Reducing the Nicotine Content of Cigarettes: Effects in Smokers With Mental Health Conditions and Socioeconomic Disadvantages

Jennifer W. Tidey PhD1, Joshua E. Muscat PhD, MPH2, Jonathan Foulds PhD2, A. Eden Evins MD, MPH3, Diann E. Gaalema PhD4, Rachel L. Denlinger-Apte MPH1

1Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, RI; 2Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA; 3Massachusetts General Hospital Center for Addiction Medicine, Harvard Medical School, Boston, MA; 4Vermont Center on Behavior and Health, University of Vermont Larner College of Medicine, Burlington, VT

Corresponding Author: Jennifer W. Tidey PhD, Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, RI 02912, USA. E-mail: Jennifer_Tidey@brown.edu

Abstract
In this commentary, we review results from laboratory studies and randomized clinical trials that have examined the effects of very low–nicotine-content cigarette use in smokers with mental health conditions and socioeconomic disadvantages. On the basis of scientific evidence to date, we conclude that a reduced-nicotine standard for cigarettes would likely reduce cigarette smoking in these populations, without increasing psychiatric symptoms or compensatory smoking.

What Are the Effects of VLNC Cigarettes on Cigarette Abuse Liability Measures in These Smokers?
Two laboratory studies have examined effects of VLNC cigarettes in smokers with MHCs. A single-site study compared responses of smokers with schizophrenia and controls to usual-brand and Quest 3 VLNC cigarettes (1.0 mg nicotine/g tobacco) plus placebo or 42 mg nicotine patches, and a multisite study compared responses to Spectrum cigarettes with normal-nicotine content (NNC; 15.8 mg/g) and reduced-nicotine content (RNC; 5.2, 2.4 and 0.4 mg/g) in smokers with past-year depression and/or anxiety disorders, those with opioid use disorders, and women with less than 12 years of education. Both studies found that smokers rated the positive subjective effects of VLNC cigarettes lower than those of usual-brand or NNC cigarettes, and the multisite study found that cigarettes with less than or equal to 5.2 mg/g nicotine were less likely to be chosen than NNC cigarettes when the effort required to obtain puffs from these cigarettes was the same. Both studies collected smoking topography and breath carbon monoxide (CO) levels and found no indication of compensatory smoking of VLNC cigarettes.

Results are also emerging from RCTs that have investigated the effects of extended VLNC cigarette use in smokers with MHCs. In a secondary analysis of a multisite RCT, smokers with elevated depressive symptoms who were randomized to Spectrum cigarettes with 2.4 mg/g nicotine or less smoked fewer cigarettes per day (CPD) at week 6 than those who were randomized to NNC cigarettes. An RCT in smokers with schizophrenia or bipolar disorder found that those randomized to Spectrum cigarettes with 0.4 mg/g nicotine...
smoked fewer CPD and had lower breath CO levels at week 6 than those who were randomized to NNC cigarettes. Preliminary topography results also indicate that total puff volume was decreased in both conditions. Finally, preliminary results from a two-arm, double-blind, parallel-group RCT that compared the effects of progressively reduced-nicotine condition (from 11.6 mg/cigarette to 0.2 mg/cigarette in 3-week steps) versus an NNC condition (11.6 mg/cigarette for 18 weeks) in 188 smokers with current or past mood and/or anxiety disorders indicate that those in the RNC condition smoked fewer CPD and had lower CO, nicotine metabolite and cigarette dependence levels at the end of the randomization phase than the NNC group. At the end of the randomization phase, all participants were encouraged to quit, and those interested in quitting were provided with nicotine replacement and brief counseling. At a follow-up session 12 weeks later, there was a higher rate of quitting (biochemically confirmed) in the reduced-nicotine condition than in the NNC condition.

Two studies have investigated the effects of VLNC cigarettes on abstinence rates in economically disadvantaged smokers. As noted earlier, a multisite laboratory study that included socioeconomically disadvantaged women found that Spectrum cigarettes with 2.4 mg/g nicotine or less were less satisfying, rewarding, and chosen less often than NNC cigarettes. Preliminary results from a two-arm, double-blind, parallel-group RCT that evaluated the effects of progressively reduced-nicotine condition (from 11.6 mg/cigarette to 0.2 mg/cigarette in 3-week steps) versus an NNC condition (11.6 mg/cigarette for 18 weeks) in 245 socioeconomically disadvantaged smokers indicate that participants in the reduced-nicotine condition smoked fewer CPD and had lower CO, nicotine metabolite, and cigarette dependence levels at the end of the randomization phase compared to the NNC group. Overall, these studies consistently support the idea that a reduced-nicotine standard for cigarettes would reduce smoking in smokers with MHCs or socioeconomic disadvantages. Importantly, all of the studies reviewed above included measures of smoking topography and/or breath CO levels and found no evidence of compensatory smoking of VLNC cigarettes. The preliminary finding of increased quitting among smokers with MHCs who underwent nicotine reduction is particularly noteworthy because none of these study participants were trying to quit when they enrolled.

Does VLNC Cigarette Use Exacerbate Psychiatric or Other Symptoms in Smokers With MHCs? To date, no studies have reported that VLNC cigarette use exacerbates psychiatric symptoms in smokers with MHCs. Preliminary results from a two-arm, double-blind, parallel-group RCT that evaluated the effects of progressively reduced-nicotine content versus NNC cigarettes in 188 smokers with current or past mood and/or anxiety disorders indicate that the groups did not differ on measures of depression, anxiety, or mental distress throughout the trial. A secondary analysis from a multisite RCT found that smokers with elevated depressive symptoms who were randomized to use Spectrum cigarettes with less than or equal to 2.4 mg/g nicotine actually had significantly lower depressive symptoms at week 6 than those randomized to NNC cigarettes. However, cognitive performance is one area of functioning that may be negatively affected by nicotine reduction. A laboratory study that investigated the effects of Quest 3 (1.0 mg/g nicotine) and usual-brand cigarettes in smokers with schizophrenia and controls found no effects on psychiatric symptoms, but decrements in cognitive task performance were observed in both the patient and control groups, which were attenuated with concurrent nicotine replacement. In summary, studies to date do not suggest that a reduced-nicotine standard for cigarettes would exacerbate psychiatric symptoms in smokers with MHCs. However, there is some indication that heavy smokers (with or without schizophrenia) might experience cognitive performance decrements, which could be mitigated with nicotine replacement.

Should the Scope of the Proposed Reduced-Nicotine Standard for Cigarettes be Expanded to Include Other Combusted Products That Are Smoked Like Cigarettes? There is a high rate of other combusted tobacco product (ie, cigars, little cigars, cigarillos, roll-your-own cigarettes) use among smokers with MHCs and socioeconomic disadvantage compared to smokers in general. In Pennsylvania, use of roll-your-own tobacco is higher among socioeconomically disadvantaged smokers because of the lower tax rate on roll-your-own tobacco. Preliminary results from a laboratory study that modeled the effects of increasing cigarette price on cigarette purchasing and substitution with non-premium cigars found a greater substitution among socioeconomically disadvantaged smokers (ie, ≤ 12 years of education) than among non-disadvantaged smokers. These studies indicate that smokers with MHCs and socioeconomic disadvantage, who are already more prone than other...
smokers to use alternative combusted tobacco products, might increase their use of alternative tobacco products if the proposed reduced-nicotine standard does not also extend to these products.

Conclusions
The evidence to date from laboratory studies and RCTs indicates that reducing the nicotine content of cigarettes to a minimally addictive level is likely to reduce cigarette smoking in smokers with MHCs and socioeconomic disadvantages, without leading to increases in psychiatric symptoms or smoke intake indicative of compensatory smoking. Preliminary findings from one study suggest that this regulation could even increase quitting among smokers with MHCs. However, smokers with MHCs might benefit from adjunctive non-combusted sources of nicotine, based on results from one study. Furthermore, because substitution of alternative tobacco products is observed in socioeconomically disadvantaged smokers when access to cigarettes is restricted through price increases, a reduced-nicotine standard might lead to increased use of alternative combusted tobacco products if the standard does not also extend to these products.

Funding
Preparation of this manuscript was supported by grants U54DA031659, U54DA036114, P50DA036107 and R36DA04183 from the National Institute on Drug Abuse (NIDA) and the Food and Drug Administration (FDA) Center for Tobacco Products. The content is solely the responsibility of the authors and does not necessarily represent the official views of NIDA or the FDA.

Declaration of Interests
None declared.

References
1. Phillips E, Wang TW, Husten CG, et al. Tobacco product use among adults - United States, 2015. MMWR Morb Mortal Wkly Rep. 2017;66(44):1209–1215. https://www.cdc.gov/mmwr/volumes/66/wr/mm6644a2.htm. Accessed March 27, 2019.
2. Prochaska JJ, Das S, Young-Wolff KC. Smoking, mental illness, and public health. Annu Rev Public Health. 2017;38:165–185. doi: 10.1146/annurev-publhealth-031816-044618.
3. Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM, AhnAllen CA. Separate and combined effects of very low nicotine cigarettes and nicotine replacement, in smokers with schizophrenia and controls. Nicotine Tob Res. 2013;15(1):121–129. doi: 10.1093/ntr/ntq098.
4. Higgins ST, Heil SH, Sigmun SC, et al. Addiction potential of cigarettes with reduced nicotine content in populations with psychiatric disorders and other vulnerabilities to tobacco addiction. JAMA Psychiatry. 2017;74(10):1056–1064. doi: 10.1001/jamapsychiatry.2017.2335.
5. Tidey JW, Cassidy RN, Miller ME. Smoking topography characteristics of very low nicotine content cigarettes, with and without nicotine replacement, in smokers with schizophrenia and controls. Nicotine Tob Res. 2016;18(9):1807–1812. doi: 10.1093/ntr/ntw089.
6. Donny EC, Denlinger RL, Tidey JW, et al. Randomized trial of reduced-nicotine standards for cigarettes. N Engl J Med. 2015;373(14):1340–1349. doi: 10.1056/NEJMsa1502403.
7. Tidey JW, Pacek LR, Koopmaners JS, et al. Effects of 6-week use of reduced-nicotine content cigarettes in smokers with and without elevated depressive symptoms. Nicotine Tob Res. 2017;19(1):59–67.
8. Tidey JW, Colby SM, Denlinger-Apte R, et al. Effects of six-week use of very low nicotine content cigarettes in smokers with serious mental illness. Nicotine Tob Res. This issue.
9. Denlinger-Apte R, Tidey J, Lindgren B, et al. Smoking topography characteristics during a six-week trial of very low nicotine content cigarettes in smokers with serious mental illness. In: Presented at the Society for Research on Nicotine and Tobacco 2019 Annual Conference; February 20–23, 2019; San Francisco, CA. https://cdn.ymaws.com/www.srnt.org/resource/resmgr/SRNT19_Abstracts.pdf. Accessed March 27, 2019.
10. Foulds J, Veldheer S, Pachas G, et al. A double-blind randomized controlled trial of reduced nicotine cigarettes in smokers with mood and anxiety disorders. In: Presented at the Society for Research on Nicotine and Tobacco 2019 Annual Conference; February 20–23, 2019; San Francisco, CA. https://cdn.ymaws.com/www.srnt.org/resource/resmgr/SRNT19_Abstracts.pdf. Accessed March 27, 2019.
11. Veldheer S, Liao J, Krebs N, et al. Quit rates among smokers with mood and anxiety disorders participating in a randomized controlled trial of reduced nicotine content cigarettes. In: Presented at the Society for Research on Nicotine and Tobacco 2019 Annual Conference; February 20–23, 2019; San Francisco, CA. https://cdn.ymaws.com/www.srnt.org/resource/resmgr/SRNT19_Abstracts.pdf. Accessed March 27, 2019.
12. Krebs NM, Zhu J, Veldheer S, et al. Switching to progressively reduced nicotine content cigarettes in smokers with low socioeconomic status. Presented at the Society for Research on Nicotine and Tobacco 2019 Annual Conference. February 20–23, 2019; San Francisco, CA. https://cdn.ymaws.com/www.srnt.org/resource/resmgr/SRNT19_Abstracts.pdf. Accessed March 27, 2019.
13. Gaaleta DE, Tidey JW, Davis DR, et al. Potential moderating effects of psychiatric diagnosis and symptom severity on subjective and behavioral responses to reduced nicotine content cigarettes. Nicotine Tob Res. This issue.
14. Walker N, Howe C, Bullen C, et al. The combined effect of very low nicotine content cigarettes, used as an adjunct to usual Quitline care (nicotine replacement therapy and behavioural support), on smoking cessation: a randomized controlled trial. Addiction. 2012;107(10):1857–1867. doi: 10.1111/j.1360-0443.2012.03906.x.
15. AhnAllen CG, Bidwell LC, Tidey JW. Cognitive effects of very low nicotine content cigarettes, with and without nicotine replacement, in smokers with schizophrenia and controls. Nicotine Tob Res. 2015;17(5):510–514. doi: 10.1093/ntr/ntu163.
16. Joseph S, Krebs NM, Zhu J, et al. Differences in nicotine dependence, smoke exposure and consumer characteristics between smokers of machine-injected roll-your-own cigarettes and factory-made cigarettes. Drug Alcohol Depend. 2018;187:109–115. doi: 10.1016/j.drugalcdep.2018.01.039.
17. Tidey JW, Miller ME, Cassidy R, Denlinger-Apte R. Reinforcing efficacy of cigarettes vs. little cigars in smokers differing in socioeconomic status. Presented at the Conference on Problems of Drug Dependence 2018 Annual Meeting, Date, 2019; San Diego, CA. https://cpdd.org/wp-content/uploads/2018/06/abstracts_2018_Edited.pdf. Accessed March 27, 2019.